Xue Zeng

Title: Xue Zeng and Research on Inactive Telomerase

Introduction

Xue Zeng is an inventor associated with Taizhou, China, whose patent work addresses telomerase activity and telomere shortening in non-dividing cells. The supplied information lists 1 patent and identifies Zhejiang Juvensis Therapeutics Co., Ltd. and Nanjing Juvensis Therapeutics Co., Ltd. among the companies he has worked with.

Latest Patents

The listed patent, “Inactive Telomerase, Adenovirus Associated Virus and Artificial mRNA Having Same and Use Thereof,” describes a double-mutant telomerase with Y707F and D868A mutation sites. It also covers adenovirus-associated and artificial mRNA forms of the inactive telomerase, and their proposed use in treating diseases associated with telomere shortening in non-dividing cells.

According to the patent description, the design aims to inhibit TERT activity while keeping telomerase in the nucleus. This approach is intended to protect telomeres from shortening while limiting excessive telomere lengthening that could contribute to carcinogenesis.

Career Highlights

The supplied career information connects Zeng with Zhejiang Juvensis Therapeutics Co., Ltd. and Nanjing Juvensis Therapeutics Co., Ltd. His listed patent focuses on a molecular approach to balancing telomere protection with control of telomerase activity.

Collaborations

Jiahao Zhang is identified as a coworker. The supplied information describes Zhang as a woman.

Conclusion

Xue Zeng’s listed invention explores inactive telomerase as a potential way to protect telomeres in non-dividing cells while reducing risks associated with excessive telomerase activity.